Bio-Gene Technology: Pioneering Bio-Insecticides with $3M U.S. Department of Defense Grants

Key Highlights

• Secured two U.S. Department of Defense grants totaling AUD 3M (USD 1.9M).
• Projects to develop Flavocide® and Qcide® for military and civilian applications.
• Addressing global challenges of insecticide resistance and vector-borne diseases.

Bio-Gene Technology Ltd (ASX: BGT) has emerged as a key innovator in bio-insecticides, recently securing AUD 3 million in competitive grants from the U.S. Department of Defense’s Deployed Warfighter Protection (DWFP) program. These grants validate Bio-Gene’s (ASX: BGT) technology and its potential to combat insecticide resistance and safeguard both military personnel and civilians from vector-borne diseases.

Flavocide® and Qcide®: Breakthrough Innovations

The first grant, worth AUD 1.6 million, supports the development of a wearable product containing Flavocide®, designed to act as a passive spatial repellent and toxicant. This device, developed in collaboration with GearJump Technologies and other research organizations, targets flying insect vectors such as mosquitoes.

The second grant, valued at AUD 1.4 million, focuses on creating a sprayable formulation of Qcide® for controlling bed bugs and flies. This product aims to provide long-lasting protection on various surfaces, addressing both military and civilian needs.

Flavocide® and Qcide®, derived from naturally occurring compounds, represent a novel approach to pest control. Flavocide’s unique mode of action effectively overcomes insecticide resistance, a growing global concern.

Strategic Partnerships and Global Impact

Bio-Gene Technology’s (ASX: BGT) collaborations with leading institutions, including the U.S. Army Combat Capabilities Development Command and the Walter Reed Army Institute of Research, underscore the global significance of this initiative. The DWFP program, launched in 2004, aims to develop integrated vector control systems and commercialize innovative solutions for public health.

The civilian market potential is immense. With vector-borne diseases causing over 700,000 deaths annually and the bed bug control market projected to grow from USD 2.3 billion in 2023 to USD 4.9 billion by 2032, Bio-Gene Technology (ASX: BGT) is well-positioned to capture significant market share.

Stock Performance Reflects Market Optimism

Bio-Gene Technology’s (ASX: BGT) stock price soared 84.38% on January 29, 2025, to close at AUD 0.059, following the grant announcement. Trading volume reached 22.3 million shares, far exceeding the four-week average of 61,185 shares, signaling strong investor confidence. The stock has also delivered a 51.28% gain over the past month and a 37.21% year-to-date increase, reinforcing positive market sentiment.

Looking Ahead

Bio-Gene Technology’s (ASX: BGT) innovative bio-insecticides are poised to disrupt traditional pest control markets, offering safer and more effective alternatives. The company’s focus on addressing global challenges of insecticide resistance and vector-borne diseases aligns with growing demand for sustainable solutions in both military and civilian sectors.

A Transformative Milestone

The U.S. Department of Defense grants mark a transformative moment for Bio-Gene Technology (ASX: BGT). By advancing Flavocide® and Qcide® development, the company is not only reinforcing its leadership in bio-insecticides but also contributing to global health and safety. Investors and stakeholders alike should watch Bio-Gene Technology (ASX: BGT) closely as it continues to redefine the future of pest control.

Bio-Gene Technology’s (ASX: BGT) partnerships, innovative pipeline, and surging stock performance highlight its potential to deliver both financial returns and societal impact. The company is a compelling opportunity in the bio-insecticide market.